# Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

> **NCT00251550** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 12 (—)

## Conditions studied

- Malignant Pleural Mesotherioma

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00251550
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 12 (—)
- **Last updated:** 2007-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251550, "Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00251550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*